Continued embrace of precision dosing will reduce costs and optimize clinical outcomes.
Yaning Wang, PhD
Advertisement
CEO, Createrna Science and Technology, former Director of FDA’s Division of Pharmacometrics
Articles by Yaning Wang, PhD
Collecting PK data in late phase trials led to alleviating additional trials, drug approval, and better dosing.
Advertisement
Latest Updated Articles
PK in Late Phase TrialsPublished: February 1st 2012 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Imfinzi Plus FLOT Significantly Improves Overall Survival in Gastric and Gastroesophageal Cancer
2
Adaptive Trial Design as a Pathway to Faster Development
3
Applied Clinical Trials: October 2025 Interactive Digital Edition
4
After the Trial is too Late: The Case for More Active Use of Patient-Reported Outcomes in Oncology Studies
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
